Journal of Gastrointestinal Cancer

, Volume 48, Issue 3, pp 288–290 | Cite as

Enlighting the Shadow for Advanced Hepatocellular Carcinoma: Immunotherapy with Immune Checkpoint Inhibitors

  • Berksoy SahinEmail author
Review Article


Hepatocellular carcinoma has still been one of the cancer with increasing incidence and highest mortality rate in the world. Although many new promising developments have been defined in hepatocarcinogenesis, with a short survival the treatment of patients with advanced hepatocellular carcinoma is an emerging issue. On the recent decade, only one anti-angiogenic agent sorafenib improved overall survival with costing a hardly manageable toxicity. Novel immunotherapeutic agents, especially immune checkpoint inhibitors are on the edge of more effective but less toxic treatments for these patients. In this article the activity of immune checkpoint inhibitors, anti-CTLA-4 and anti-PD1 antibodies for the treatment of patients with advanced hepatocellular cancer will be reviewed.


Hepatocellular carcinoma Immunotherapy Immune checkpoint inhibitors Anti-CTLA-4 Anti-PD1 


  1. 1.
    International Agency for Research on Cancer. GLOBOCAN. Estimated Global Cancer Incidence, Mortality and Prevalence Worldwide in. 2012:2012. Accessed August 04, 2017
  2. 2.
    Whittaker S, et al. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010;29:4989–5005.CrossRefGoogle Scholar
  3. 3.
    Llovet JM, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.CrossRefGoogle Scholar
  4. 4.
    Subramanian S, et al. A review of hepatocellular carcinoma (HCC) staging systems. Chin Clin Oncol. 2013;2:33.Google Scholar
  5. 5.
    Llovet JM, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.CrossRefGoogle Scholar
  6. 6.
    Kane RC, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist. 2009;14:95–100.CrossRefGoogle Scholar
  7. 7.
    Cheng A-L et al. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol 35, 2017 (suppl; abstr 4001).Google Scholar
  8. 8.
    Zhu AX, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859–70.CrossRefGoogle Scholar
  9. 9.
    Bruix J, et al. Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial. Annals of Oncol, 27, 2016 suppl LBA-3, ii140–ii141.CrossRefGoogle Scholar
  10. 10.
    Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.CrossRefGoogle Scholar
  11. 11.
    Breous E, Thimme R. Potential of immunotherapy for hepatocellular carcinoma. J Hepatol. 2011;54(4):830–4.CrossRefGoogle Scholar
  12. 12.
    Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.CrossRefGoogle Scholar
  13. 13.
    Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer—preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010;37(5):430–9.CrossRefGoogle Scholar
  14. 14.
    Mizukoshi E, Nakamoto Y, Arai K, et al. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology. 2011;53:1206–16.CrossRefGoogle Scholar
  15. 15.
    Flecken T, Schmidt N, Hild S, et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology. 2014;59:1415–26.CrossRefGoogle Scholar
  16. 16.
    Umemoto Y, et al. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy. J Gastroenterol. 2015;50(1):65–75.CrossRefGoogle Scholar
  17. 17.
    Grakoui A, et al. Turning on the off switch: regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. J Hepatol. 2006;45(4):468–72.CrossRefGoogle Scholar
  18. 18.
    Schmidt J, et al. T-cell responses in hepatitis B and C virus infection: similarities and differences. Emerg Microbes Infect. 2013;2(3):e15.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59:81–8.CrossRefGoogle Scholar
  20. 20.
    Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66:545–51.CrossRefGoogle Scholar
  21. 21.
    El-Khoueiry AB, et al. Phase 1/2 safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the CheckMate 040 dose-escalation study. Poster presentation at ASCO. 2016; poster 4012Google Scholar
  22. 22.
    Sangro B, Melero I, Yau T et al. Safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of dose-expansion cohorts from the phase 1/2 checkmate 040 study. In:Presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO); June 3–7, 2016; Chicago, IL, USA, poster 4078.Google Scholar
  23. 23.
    Crocenzi T S. Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. J Clin Oncol 35, 2017 (suppl; abstr 4013).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Medical Oncology DepartmentCukurova UniversityAdanaTurkey

Personalised recommendations